| scholarly article | Q13442814 |
| P50 | author | Nicholas Funderburg | Q56562708 |
| Grace Mccomsey | Q90899761 | ||
| P2093 | author name string | Liang Fang | |
| Moupali Das | |||
| Yafeng Zhang | |||
| Tammy Bannerman | |||
| Andrew Cheng | |||
| Marshall W Fordyce | |||
| Scott McCallister | |||
| Qinghua Song | |||
| Hui C Liu | |||
| Jason Dinoso | |||
| Bernadette Thornton | |||
| Jessica Mantini | |||
| Manjusha Kulkarni | |||
| P2860 | cites work | Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 |
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients | Q27024262 | ||
| Inflammatory and coagulation biomarkers and mortality in patients with HIV infection | Q28473903 | ||
| Inflammation, coagulation and cardiovascular disease in HIV-infected individuals | Q28483645 | ||
| General cardiovascular risk profile for use in primary care: the Framingham Heart Study | Q29614189 | ||
| Systemic effects of inflammation on health during chronic HIV infection | Q33577551 | ||
| Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy | Q33862741 | ||
| Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection | Q33899641 | ||
| Residual immune dysregulation syndrome in treated HIV infection | Q34020121 | ||
| A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. | Q34032537 | ||
| 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis | Q34134900 | ||
| Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection | Q34315572 | ||
| Plasma levels of soluble CD14 independently predict mortality in HIV infection | Q34764002 | ||
| Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o | Q35000905 | ||
| Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens | Q35036648 | ||
| Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. | Q35102590 | ||
| Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients | Q35465943 | ||
| Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells | Q35557198 | ||
| Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. | Q35655728 | ||
| Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. | Q36436569 | ||
| Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study | Q36721012 | ||
| Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. | Q36870864 | ||
| Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system | Q37080111 | ||
| Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel | Q37234729 | ||
| Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. | Q37294964 | ||
| Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence | Q37857483 | ||
| Bone health and human immunodeficiency virus infection | Q38095828 | ||
| A Test in Context: High-Sensitivity C-Reactive Protein | Q38439507 | ||
| Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial | Q38459510 | ||
| Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda | Q38869763 | ||
| Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results | Q39599742 | ||
| Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress | Q40332526 | ||
| Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study | Q40922158 | ||
| Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials | Q41044551 | ||
| The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial | Q41337231 | ||
| Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. | Q42205327 | ||
| Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study | Q42658845 | ||
| Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study | Q42912276 | ||
| Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. | Q51352554 | ||
| 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk | Q57413870 | ||
| Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group | Q73088406 | ||
| P921 | main subject | tenofovir | Q155954 |
| inflammation | Q101991 | ||
| P304 | page(s) | 321-327 | |
| P577 | publication date | 2016-10-11 | |
| P1433 | published in | EBioMedicine | Q24912341 |
| P1476 | title | Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide | |
| P478 | volume | 13 |
| Q42328120 | Beyond Undetectable Viral Load: Effect of Nucleotides on Inflammation |
| Q55512944 | Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015. |
| Q49788771 | Concomitant AIDS cholangiopathy and Fanconi syndrome as complications of HIV in a single patient |
| Q38836878 | Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection |
| Q33912595 | Inflammation, Immune Activation, and Antiretroviral Therapy in HIV |
| Q92801350 | Plasma Lipoprotein-associated Phospholipase A2 and Superoxide Dismutase are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment |
Search more.